Zivo Bioscience receives $1M bridge loan from CEO John Payne with 10% interest and warrants

Zivo Bioscience, Inc.

CEO John Payne provides $1M unsecured six-month loan at 10% simple interest, extendable six months.
Warrants to purchase 390,000 shares at $2.91 per share, exercisable for three years.
Proceeds for working capital, coccidiosis validation study in broiler chickens, and strategic alternatives.
Company expects to complete titration study in May 2023, then 42-day study in over 2,000 chickens by mid-2023.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.